Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683379 · ClinicalTrials.gov registry record
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
A clinical trial of Duchenne Muscular Dystrophy, sponsored by REGENXBIO.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05683379 is a study of Duchenne Muscular Dystrophy that is actively recruiting participants, run by REGENXBIO. The registered enrollment target is 200 participants, below the 408-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05683379, a study of Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by REGENXBIO.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST AAV8 DetectCDx
Study Locations (1)
Georgia
- Rare Disease Research - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2026-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05683379
The ClinicalTrials.gov registry entry for NCT05683379 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 408-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (51% lower). The listed sponsor is REGENXBIO, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which AAV8 DetectCDx is the first listed.
NCT05683379 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05683379 about?
NCT05683379 is a clinical study titled "AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD". This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
What is the current status of trial NCT05683379?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2022-12-20. Estimated completion is 2026-09.
What conditions does trial NCT05683379 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy.
What interventions are being tested in trial NCT05683379?
The interventions under investigation include: AAV8 DetectCDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05683379?
This trial is sponsored by REGENXBIO, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683379 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.